Stockscreener 앱 받기
15.67
3.09%
0.47
전일 마감가:
$15.20
열려 있는:
$15.525
하루 거래량:
8.84M
Relative Volume:
1.44
시가총액:
$2.19B
수익:
$67.67M
순이익/손실:
$-412.69M
주가수익비율:
-4.095
EPS:
-3.8266
순현금흐름:
$-395.87M
1주 성능:
+26.88%
1개월 성능:
+23.48%
6개월 성능:
+76.46%
1년 성능:
+63.23%
1일 변동 폭
$15.04
$16.20
1주일 범위
$11.95
$16.73
52주 변동 폭
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
15.67 | 2.19B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Strength seen in Intellia Therapeutics (NTLA): Can its 23.2% jump turn into more strength? - MSN
Intellia Therapeutics (NTLA) Surges 12.9% Amid Positive Market M - GuruFocus
Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price - GuruFocus
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads - StocksToTrade
NTLA Stock Jumps As Intellia’s HAE Gene-Editing Data Impresses Wall Street - timothysykes.com
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
This Stock Is Up 58% This Year. Is It too Late to Buy? - The Motley Fool
This Stock Is Up 58% This Year. Is It too Late to Buy? - The Motley Fool
Physician Views Preview: Can Intellia's lonvo-z turn CRISPR promise into HAE practice? - FirstWord Pharma
NTLA Maintained by Canaccord Genuity -- Price Target Stays at $4 - GuruFocus
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - The Globe and Mail
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $19 to $49 - Moomoo
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo! Finance Canada
Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema - BioSpace
Canaccord reiterates Intellia stock rating on positive trial data - Investing.com
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail
Intellia Therapeutics Inc (NTLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intellia's Treatment Candidate Shows Promising Results - Intellectia AI
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²
Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative
Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada
Intellia Therapeutics | 8-K: Current report - Moomoo
NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com South Africa
NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga
Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView
Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan
Why is NTLA stock jumping 5% premarket today? - MSN
H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com
Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on positive trial data - Investing.com
H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus
Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization - Sahm
Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):